ECSP20021132A - Enantiómeros de tiazoles sustituidos compuestos antivirales - Google Patents
Enantiómeros de tiazoles sustituidos compuestos antiviralesInfo
- Publication number
- ECSP20021132A ECSP20021132A ECSENADI202021132A ECDI202021132A ECSP20021132A EC SP20021132 A ECSP20021132 A EC SP20021132A EC SENADI202021132 A ECSENADI202021132 A EC SENADI202021132A EC DI202021132 A ECDI202021132 A EC DI202021132A EC SP20021132 A ECSP20021132 A EC SP20021132A
- Authority
- EC
- Ecuador
- Prior art keywords
- enanthomers
- antiviral compounds
- thiazoles substituted
- thiazoles
- substituted
- Prior art date
Links
- 230000000840 anti-viral effect Effects 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 title abstract 2
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical group C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 title 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 abstract 1
- 239000003443 antiviral agent Substances 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/44—Acylated amino or imino radicals
- C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/54—Nitrogen and either oxygen or sulfur atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Abstract
La presente invención se refiere a nuevos compuestos antivirales con estereoconfiguración específica, especialmente a nuevos enantiómeros específicos, a un proceso para su preparación y a su uso como medicamentos, en particular como medicamentos antivirales.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17195047 | 2017-10-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP20021132A true ECSP20021132A (es) | 2020-07-31 |
Family
ID=60022026
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECSENADI202021132A ECSP20021132A (es) | 2017-10-05 | 2020-04-03 | Enantiómeros de tiazoles sustituidos compuestos antivirales |
Country Status (37)
| Country | Link |
|---|---|
| US (4) | US11278534B2 (es) |
| EP (2) | EP3692039B1 (es) |
| JP (1) | JP7215689B2 (es) |
| KR (1) | KR102708082B1 (es) |
| CN (1) | CN111433203B (es) |
| AR (1) | AR113344A1 (es) |
| AU (1) | AU2018344471B2 (es) |
| CA (1) | CA3077397A1 (es) |
| CL (1) | CL2020000869A1 (es) |
| CR (1) | CR20200154A (es) |
| DK (1) | DK3692039T3 (es) |
| EA (1) | EA202090620A1 (es) |
| EC (1) | ECSP20021132A (es) |
| ES (1) | ES2939652T3 (es) |
| FI (1) | FI3692039T3 (es) |
| HR (1) | HRP20230158T1 (es) |
| HU (1) | HUE061307T2 (es) |
| IL (1) | IL273681B2 (es) |
| JO (1) | JOP20200110B1 (es) |
| LT (1) | LT3692039T (es) |
| MA (1) | MA50609B1 (es) |
| MD (1) | MD3692039T2 (es) |
| MX (1) | MX2020003369A (es) |
| MY (1) | MY202544A (es) |
| NI (1) | NI202000025A (es) |
| PH (1) | PH12020550132A1 (es) |
| PL (1) | PL3692039T3 (es) |
| PT (1) | PT3692039T (es) |
| RS (1) | RS64000B1 (es) |
| SG (1) | SG11202002420SA (es) |
| SI (1) | SI3692039T1 (es) |
| SM (1) | SMT202300080T1 (es) |
| TW (1) | TWI706941B (es) |
| UA (1) | UA126163C2 (es) |
| UY (1) | UY37917A (es) |
| WO (1) | WO2019068817A1 (es) |
| ZA (1) | ZA202002150B (es) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3692039T3 (pl) * | 2017-10-05 | 2023-04-17 | Innovative Molecules Gmbh | Enancjomery podstawionych tiazoli jako związki przeciwwirusowe |
| US11760701B2 (en) | 2018-02-27 | 2023-09-19 | The Research Foundation For The State University Of New Yrok | Difluoromethoxylation and trifluoromethoxylation compositions and methods for synthesizing same |
| TW202038947A (zh) | 2018-11-28 | 2020-11-01 | 德商創新分子有限責任公司 | 在與溶瘤病毒之組合療法中治療癌症的解旋酶引子酶抑制劑 |
| AU2021367976A1 (en) | 2020-10-29 | 2023-06-08 | Innovative Molecules Gmbh | Deuterated aminothiazole compounds as antiviral compounds |
| PY2302301A (es) * | 2022-01-17 | 2023-10-31 | Innovative Molecules Gmbh | Formas cristalinas sólidas de inhibidores de helicasa-primasa y proceso de preparación de las mismas |
| EP4580601A1 (en) | 2022-08-29 | 2025-07-09 | Assembly Biosciences, Inc. | Pharmaceutical compositions for herpes virus |
| WO2024049760A1 (en) | 2022-08-29 | 2024-03-07 | Assembly Biosciences, Inc. | Cyclic urea thiazolyl compounds for treatment of hsv |
| IL325911A (en) | 2023-07-17 | 2026-03-01 | Innovative Molecules Gmbh | Micronized crystalline hydrochloride salts of antiviral helicase-primase inhibitor compounds |
| KR20260116185A (ko) | 2023-11-22 | 2026-07-28 | 어셈블리 바이오사이언시스, 인크. | 헤르페스 바이러스(hsv) 치료용 아제티딘 화합물 |
| US20260014154A1 (en) | 2024-07-12 | 2026-01-15 | Assembly Biosciences, Inc. | Cyclic urea thiazolyl compound for treatment of viral infections unresponsive to treatment with a first antiviral therapy |
| WO2026035899A1 (en) | 2024-08-07 | 2026-02-12 | Assembly Biosciences, Inc. | Azetidine compounds for treatment of hsv |
| WO2026035901A1 (en) | 2024-08-07 | 2026-02-12 | Assembly Biosciences, Inc. | Tricyclic compounds for treatment of hsv |
| WO2026035900A1 (en) | 2024-08-07 | 2026-02-12 | Assembly Biosciences, Inc. | Tricyclic compounds for treatment of hsv |
| WO2026078039A1 (en) | 2024-10-09 | 2026-04-16 | Innovative Molecules Gmbh | Oral administration forms of antiviral helicase-primase inhibitors |
| CN121873064A (zh) * | 2024-10-17 | 2026-04-17 | 博远医药(苏州)有限公司 | 杂环类衍生物及其药物组合物和应用 |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2075560A5 (es) | 1970-01-16 | 1971-10-08 | Shell Int Research | |
| NZ331104A (en) | 1995-12-29 | 2000-03-27 | Boehringer Ingelheim Ca Ltd | Phenyl thiazole derivatives that inhibit herpes replication by inhibiting the herpes helicase primase enzyme complex |
| US6040321A (en) | 1997-11-12 | 2000-03-21 | Bristol-Myers Squibb Company | Aminothiazole inhibitors of cyclin dependent kinases |
| AU3289299A (en) | 1998-02-19 | 1999-09-06 | Tularik Inc. | Antiviral agents |
| ATE229945T1 (de) | 1998-03-19 | 2003-01-15 | Upjohn Co | Zur behandlung von cmv infektionen geeignete 1,3, 4-thiadiazole |
| US6500817B1 (en) | 1999-03-08 | 2002-12-31 | Bayer Aktiengesellschaft | Thiazolyl urea derivatives and their utilization as antiviral agents |
| DE19959958A1 (de) | 1999-12-13 | 2001-08-30 | Bayer Ag | Thiazolylharnstoff-Derivate |
| DE19927415A1 (de) | 1999-06-16 | 2000-12-21 | Bayer Ag | Indolinylharnstoffderivate |
| DOP2000000109A (es) * | 1999-12-23 | 2002-08-30 | Gerald Kleymann | Derivados de tiazolilamida |
| DE10039265A1 (de) | 2000-08-11 | 2002-02-21 | Bayer Ag | Thiazolylamid-Derivate |
| EP1319185A1 (en) | 2000-06-15 | 2003-06-18 | Bayer Aktiengesellschaft | Method for identifying compounds with anti-herpes activity |
| DE10038022A1 (de) | 2000-08-04 | 2002-02-14 | Bayer Ag | Inverse Thiazolylamid-Derivate |
| DE10044353A1 (de) | 2000-09-07 | 2002-04-04 | Bayer Ag | Unkompetitive Inhibitoren der Helikase-Primase |
| DE10044358A1 (de) | 2000-09-07 | 2002-03-21 | Bayer Ag | Thiazolylcarbonylheterocyclyl-Derivate |
| DE10044328A1 (de) | 2000-09-07 | 2002-03-21 | Bayer Ag | Thiazolylcarbonyl-Derivate |
| DE10129715A1 (de) * | 2001-06-22 | 2003-01-02 | Bayer Ag | Thiazolylamide |
| DE10129717A1 (de) | 2001-06-22 | 2003-01-02 | Bayer Ag | Kombinationspräparate zur Herpes-Behandlung |
| DE10129714A1 (de) | 2001-06-22 | 2003-01-02 | Bayer Ag | Topische Anwendung von Thiazolylamiden |
| DE10129716A1 (de) | 2001-06-22 | 2003-01-02 | Bayer Ag | Kombinationspräparate zur Herpes-Behandlung |
| DE10131128A1 (de) | 2001-06-28 | 2003-01-16 | Bayer Ag | Sekundäre Sulfonamide |
| DE10210319A1 (de) | 2002-03-08 | 2003-09-18 | Bayer Ag | Thiazolylcarbonyl-Derivate |
| DE10235967B4 (de) | 2002-08-06 | 2005-09-08 | Bayer Healthcare Ag | Methode zum Identifizieren von Substanzen mit antimikrobieller Wirkung |
| DE10300109A1 (de) | 2003-01-07 | 2004-07-15 | Bayer Healthcare Ag | Methode zur Inhibition der Replikation von Herpesviren |
| BRPI0507278A (pt) | 2004-01-30 | 2007-06-26 | Vertex Pharma | moduladores dos transportadores do cassete de ligação ao atp |
| DE102005014248A1 (de) | 2005-03-30 | 2006-10-05 | Aicuris Gmbh & Co. Kg | Pharmazeutische Zubereitung von N-[5-(Aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamid |
| US8548554B2 (en) | 2006-12-08 | 2013-10-01 | Fraunhofer-Gesellschaft Zur Forderung Der Angewandten Forschung E.V. | Dry electrode cap for electro-encephalography |
| DE102010046720A1 (de) | 2010-09-23 | 2012-03-29 | Bayer Schering Pharma Aktiengesellschaft | Verfahren zur Herstellung von pan-CDK-Inhibitoren der Formel (l), sowie Intermediate der Herstellung |
| CN103269593A (zh) * | 2010-11-01 | 2013-08-28 | 罗马克实验室有限公司 | 烷基亚磺酰基取代的噻唑化物化合物 |
| TW201636330A (zh) | 2011-05-24 | 2016-10-16 | 拜耳知識產權公司 | 含有硫醯亞胺基團之４－芳基－ｎ－苯基－１，３，５－三氮雜苯－２－胺 |
| EP2573086A1 (en) | 2011-09-26 | 2013-03-27 | AiCuris GmbH & Co. KG | N-[5-(Aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide mesylate monohydrate |
| PH12018501979B1 (en) | 2016-04-06 | 2023-05-05 | Innovative Molecules Gmbh | Aminothiazole derivatives useful as antiviral agents |
| ES2877854T3 (es) | 2016-11-28 | 2021-11-17 | Aicuris Gmbh & Co Kg | Una sal de maleato de la base libre de N-[5-(aminosulfonil)-4-metil-1,3-tiazol-2-il]-N-metil-2-[4-(2-piridinil)-fenil]-acetamida, formulaciones farmacéuticas, procedimientos de fabricación y usos de las mismas para el tratamiento de los virus del herpes |
| TW201825095A (zh) | 2016-11-28 | 2018-07-16 | 德商艾庫里斯抗感染治療有限公司 | 包含n-[5-(胺基磺醯基)-4-甲基-1,3-噻唑-2-基]-n-甲基-2-[4-(2-吡啶基)-苯基]-乙醯胺之局部醫藥調配物 |
| TWI811800B (zh) | 2016-11-28 | 2023-08-11 | 德商艾庫瑞斯公司 | N-[5-(胺基磺醯基)-4-甲基-1,3-噻唑-2-基]-n-甲基-2-[4-(2-吡啶基)-苯基]-乙醯胺游離鹼半水合物、製造方法及其用途 |
| WO2018127207A1 (zh) | 2017-01-09 | 2018-07-12 | 南京明德新药研发股份有限公司 | 噻唑衍生物及其应用 |
| PL3692039T3 (pl) * | 2017-10-05 | 2023-04-17 | Innovative Molecules Gmbh | Enancjomery podstawionych tiazoli jako związki przeciwwirusowe |
-
2018
- 2018-10-04 PL PL18779696.6T patent/PL3692039T3/pl unknown
- 2018-10-04 SG SG11202002420SA patent/SG11202002420SA/en unknown
- 2018-10-04 US US16/753,814 patent/US11278534B2/en active Active
- 2018-10-04 FI FIEP18779696.6T patent/FI3692039T3/fi active
- 2018-10-04 CN CN201880065255.2A patent/CN111433203B/zh active Active
- 2018-10-04 RS RS20230156A patent/RS64000B1/sr unknown
- 2018-10-04 EP EP18779696.6A patent/EP3692039B1/en active Active
- 2018-10-04 TW TW107135101A patent/TWI706941B/zh active
- 2018-10-04 SI SI201830861T patent/SI3692039T1/sl unknown
- 2018-10-04 EA EA202090620A patent/EA202090620A1/ru unknown
- 2018-10-04 WO PCT/EP2018/077022 patent/WO2019068817A1/en not_active Ceased
- 2018-10-04 EP EP22213253.2A patent/EP4209491A1/en active Pending
- 2018-10-04 MY MYPI2020001322A patent/MY202544A/en unknown
- 2018-10-04 PT PT187796966T patent/PT3692039T/pt unknown
- 2018-10-04 SM SM20230080T patent/SMT202300080T1/it unknown
- 2018-10-04 HU HUE18779696A patent/HUE061307T2/hu unknown
- 2018-10-04 UY UY0001037917A patent/UY37917A/es active IP Right Grant
- 2018-10-04 CA CA3077397A patent/CA3077397A1/en active Pending
- 2018-10-04 LT LTEPPCT/EP2018/077022T patent/LT3692039T/lt unknown
- 2018-10-04 MA MA50609A patent/MA50609B1/fr unknown
- 2018-10-04 ES ES18779696T patent/ES2939652T3/es active Active
- 2018-10-04 AR ARP180102864A patent/AR113344A1/es active IP Right Grant
- 2018-10-04 DK DK18779696.6T patent/DK3692039T3/da active
- 2018-10-04 MD MDE20200816T patent/MD3692039T2/ro unknown
- 2018-10-04 MX MX2020003369A patent/MX2020003369A/es unknown
- 2018-10-04 HR HRP20230158TT patent/HRP20230158T1/hr unknown
- 2018-10-04 JP JP2020519403A patent/JP7215689B2/ja active Active
- 2018-10-04 IL IL273681A patent/IL273681B2/en unknown
- 2018-10-04 KR KR1020207009294A patent/KR102708082B1/ko active Active
- 2018-10-04 AU AU2018344471A patent/AU2018344471B2/en active Active
- 2018-10-04 CR CR20200154A patent/CR20200154A/es unknown
- 2018-10-04 UA UAA202002635A patent/UA126163C2/uk unknown
-
2020
- 2020-03-25 PH PH12020550132A patent/PH12020550132A1/en unknown
- 2020-04-01 NI NI202000025A patent/NI202000025A/es unknown
- 2020-04-01 CL CL2020000869A patent/CL2020000869A1/es unknown
- 2020-04-03 EC ECSENADI202021132A patent/ECSP20021132A/es unknown
- 2020-05-04 ZA ZA2020/02150A patent/ZA202002150B/en unknown
- 2020-05-07 JO JOJO/P/2020/0110A patent/JOP20200110B1/ar active
-
2022
- 2022-01-21 US US17/581,166 patent/US12295945B2/en active Active
-
2024
- 2024-06-06 US US18/736,166 patent/US12527778B2/en active Active
-
2026
- 2026-01-16 US US19/451,608 patent/US20260137669A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NI202000025A (es) | Enantiómeros de tiazoles sustituidos como compuestos antivirales | |
| NI201700096A (es) | Derivados de 4h-pirrol[3, 2-c]piridin-4-ona | |
| CO2019012957A2 (es) | Inhibidores de quinasa y usos de los mismos | |
| ECSP18074962A (es) | Derivados de aminotiazol útiles como agentes antivíricos | |
| SV2018005709A (es) | 3-azabiciclo[3.1.0]hexanos sustituidos como inhibidores de cetohexoquinasa | |
| UY34566A (es) | 1,4?dihidropirimidinas 4,4?disustituidas y su uso como medicamentos para el tratamiento de la hepatitis b | |
| DOP2017000078A (es) | Indazoles sustituidos con bencilo como inhibidores de bub1. | |
| UY36737A (es) | 3-amino-1,5,6,7-tetrahidro-4h-indol-4-onas | |
| CL2016001895A1 (es) | Compuestos | |
| CR20160450A (es) | Anticuerpos multiespecificos | |
| CL2016001973A1 (es) | Derivados de nucleosido sustituidos con 4' -difluorometilo como inhibidores de la replicación de arn de la influenza. | |
| UY36175A (es) | 3-amino-1,5,6,7-tetrahidro-4h-indol-4-onas | |
| MX2020002123A (es) | Sales de ribociclib y formas en estado sólido de las mismas. | |
| MX2018002416A (es) | Derivados de 1,7-diaril-1,6-heptadien-3,5-diona, procedimiento para la preparación y uso de los mismos. | |
| CL2016002207A1 (es) | Compuestos derivados de 1,2-dihidro-3h-pirrolo[1,2-c]imidazol-3-ona, con actividad antibacteriana gram (+) y gram (-); composicion farmacéutica que los comprende. | |
| MX2017008414A (es) | Composiciones inhibidoras de nitrificacion y metodos para preparar las mismas. | |
| BR112017001391A2 (pt) | componentes para o fusionamento de corpos vertebrais | |
| UY36602A (es) | Variantes de protoxina-ii y métodos de uso | |
| CO2017010143A2 (es) | Procesos para preparar fluorocetólidos | |
| CR20140051A (es) | Compuestos de tiazol y oxazol de bencen-sulfonamida | |
| GT201500116A (es) | Mètodo para preparar derivados de feniloximetil-nitro-imidazol y su uso del mismo | |
| UY36284A (es) | Método para la preparación de imidazopiridazinas sustituidas |